PRESS RELEASE published on 08/15/2025 at 15:21, 10 months 29 days ago enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech enVVeno Medical Corporation to present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 21, 2025, with CEO Robert Berman discussing innovative treatment solutions for deep venous disease Webinar EnVVeno Medical Corporation Bioprosthetic Solutions Deep Venous Disease Webull Financial
BRIEF published on 08/06/2025 at 14:35, 11 months 7 days ago VenoValve d'enVVeno Medical : une solution rentable pour les IVC sévères EnVVeno Medical Insuffisance Veineuse Chronique Approbation De La FDA Économies Sur Les Coûts Des Soins De Santé Valve VenoValve
BRIEF published on 08/06/2025 at 14:35, 11 months 7 days ago EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Healthcare Cost Savings
PRESS RELEASE published on 08/06/2025 at 14:30, 11 months 7 days ago Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits Webcast VenoValve Healthcare Savings CVI Cost-Effectiveness
BRIEF published on 08/04/2025 at 15:10, 11 months 9 days ago EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options FDA Approval VenoValve CVI Diagnosis Trump Impact Healthcare Cost
BRIEF published on 08/04/2025 at 15:10, 11 months 9 days ago EnVVeno Medical étudie l'impact potentiel du diagnostic d'IVC de Trump sur les options de traitement. Approbation De La FDA Valve VenoValve Diagnostic De L'IVC L'impact De Trump Coût Des Soins De Santé
PRESS RELEASE published on 08/04/2025 at 15:05, 11 months 9 days ago enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025 EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Decision Deep Venous Disease
BRIEF published on 08/01/2025 at 14:05, 11 months 12 days ago EnVVeno Medical Q2 2025 Financial Report and Corporate Update EnVVeno Medical VenoValve Q2 2025 Results EnVVe Progress FDA Decision
BRIEF published on 08/01/2025 at 14:05, 11 months 12 days ago Rapport financier et mise à jour de l'entreprise d'enVVeno Medical pour le deuxième trimestre 2025 EnVVeno Medical Valve VenoValve Résultats Du Deuxième Trimestre 2025 Progrès EnVVe Décision De La FDA
PRESS RELEASE published on 08/01/2025 at 14:00, 11 months 12 days ago enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update enVVeno Medical reports $3.8M cash burn & financial results for Q2 2025. Operations funded through Q3'2026 with sufficient cash. FDA decisions & clinical program progress on track Financial Results EnVVeno Medical Cash Burn FDA Decisions Clinical Program Progress
Published on 07/14/2026 at 01:45, 3 hours 3 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 4 hours 47 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 5 hours 38 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 7 hours 13 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 8 hours 48 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/13/2026 at 22:30, 6 hours 18 minutes ago Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 7 hours 27 minutes ago Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 7 hours 30 minutes ago EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 8 hours ago EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 20:23, 8 hours 25 minutes ago EQS-Adhoc: TRATON SE: Preliminary operating result for Q2 2026 exceeds market expectations
Published on 07/13/2026 at 18:00, 10 hours 48 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 10 hours 48 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 10 hours 48 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026